Cureus · Oct 17, 2026

Predictors of Successful Prandial Insulin Withdrawal Following the Initiation of Therapy Based on Glucagon-Like Peptide-1 (GLP-1) in Adults With Type 2 Diabetes (T2D): A Systematic Review of Clinical, Biochemical, and Treatment-Related Factors

By Elhassan LA, Abdelsalam AAHM, Ali MAM et al.

Glucagon-like peptide-1 (GLP-1)-based therapy may permit withdrawal of scheduled prandial insulin in adults with type 2 diabetes. The clinical and biochemical factors associated with successful withdrawal remain less clearly established than the feasibility of treatment simplification. PubMed, Embase, Scopus, and Web of Science were searched for publications from January 1, 2021 through September 16, 2026. The authors' final study selection comprised peer-reviewed primary research evaluating prandial insulin withdrawal, replacement, or related prognostic factors, with follow-up of at least 12 weeks. Prognostic studies, randomized trials, and other nonrandomized studies were assessed using design-specific tools. Clinical and methodological heterogeneity was addressed through narrative synthesis. Of 467 records identified, 243 duplicates were removed and 224 records were screened. Sixty-one reports underwent full-text assessment, and 15 studies were included: three randomized comparisons and 12 nonrandomized studies. Four included reports examined candidate predictors, of which two provided prandial-specific analyses. Lower baseline insulin requirements and preserved endogenous secretion were the principal signals. Other associations involved diabetes duration, baseline glycemia, microvascular complications, and supervised fasting-test glycemia, although several concerned indirect endpoints. Reported discontinuation proportions varied substantially across selected populations and follow-up periods. Prandial insulin withdrawal is feasible in selected adults receiving GLP-1-based therapy. Lower insulin requirements and preserved endogenous secretion may help identify candidates, but neither establishes a universally reliable cutoff. Broader prospective validation and consistent definitions of durable glycemic success are needed.

doi.org/10.7759/cureus.118067Open accessPubMed 43042329Interventions

AgingResearch.News